The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Circulating tumor DNA to guide furmonertinib monotherapy or combination therapy in advanced EGFR mutant non-small cell lung cancer (NSCLC): A randomized, open-label, multicenter study (FOCUS-C).
 
Wenfeng Fang
No Relationships to Disclose
 
Jun Jia
No Relationships to Disclose
 
Guanming Jiang
No Relationships to Disclose
 
Xiaofang Dong
No Relationships to Disclose
 
Zongxiao ShangGuan
No Relationships to Disclose
 
Zhengxiang Han
No Relationships to Disclose
 
Hong Shen
No Relationships to Disclose
 
Li Zhang
Consulting or Advisory Role - AstraZeneca; Innovent Biologics
Speakers' Bureau - AstraZeneca; BeiGene; HenRui; Innovent Biologics; Roche China
Research Funding - Akeso Biopharma (Inst); AstraZeneca (Inst); BMS (Inst); Chia Tai Tianqing Pharmaceutical Group (Inst); Junshi Pharmaceuticals (Inst); QiLu Pharmaceutical (Inst)